Filing Flows › Impact Biomedical (IBO) › Q2 2025
Impact Biomedical (IBO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Impact Biomedical (IBO) reported revenue of $7K for the second quarter 2025 (Q2 2025).
Impact Biomedical, Q2 2025: revenue $7K, net loss $14.4M, operating cash flow −$694K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7K | — | — |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$14.4M | — | — |
| Operating cash flow | −$694K | — | — |
What changed
Revenue was $7K in Q2 2025.
Operating costs exceeded revenue by $1.2M, an operating margin of -16471.4%. The quarter ended with a net loss of $14.4M. Minority interests bore $6K of it: to shareholders the quarter was a loss of $14.3M. Net interest and other expense of $13.2M was the main reason.
Operating cash flow was −$694K. Non-cash charges added back $288K of depreciation and amortization and $2K of share-based compensation. Working capital and other items added $13.4M.
Questions
What was Impact Biomedical's revenue in the second quarter 2025?
Impact Biomedical (IBO) reported revenue of $7K for the second quarter 2025 (Q2 2025).
Source: Impact Biomedical 10-Q on SEC EDGAR.